Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play
New York, January 21, 2026, 11:55 AM EST — Regular session Shares of Boston Scientific Corporation held steady, edging just above $91.20 during late morning trading in New York on Wednesday. The stock is steady, with investors weighing a device-safety warning from U.S. regulators while watching Boston Scientific’s latest deal moves. Attention remains on the company’s planned Penumbra acquisition, sparking…